Loading...
Please wait, while we are loading the content...
Similar Documents
IGF-I treatment improves the functional properties of fast- and slow-twitch skeletal muscles from dystrophic mice
| Content Provider | Semantic Scholar |
|---|---|
| Author | Lynch, Gordon S. Cuffe, Scott A. Plant, David R. Gregorevic, Paul |
| Copyright Year | 2001 |
| Abstract | Although insulin-like growth factor-I (IGF-I) has been proposed for use by patients suffering from muscle wasting conditions, few studies have investigated the functional properties of dystrophic skeletal muscle following IGF-I treatment. 129P1 ReJ-Lama2(dy) (129 ReJ dy/dy) dystrophic mice suffer from a deficiency in the structural protein, laminin, and exhibit severe muscle wasting and weakness. We tested the hypothesis that 4 weeks of IGF-I treatment ( approximately 2 mg/kg body mass, 50 g/h via mini-osmotic pump, subcutaneously) would increase the mass and force producing capacity of skeletal muscles from dystrophic mice. IGF-I treatment increased the mass of the extensor digitorum longus (EDL) and soleus muscles of dystrophic mice by 20 and 29%, respectively, compared with untreated dystrophic mice (administered saline-vehicle only). Absolute maximum force (P(o)) of the EDL and soleus muscle was increased by 40 and 32%, respectively, following IGF-I treatment. Specific P(o) (sP(o)) was increased by 23% in the EDL muscles of treated compared with untreated mice, but in the soleus muscle sP(o) was unchanged. IGF-I treatment increased the proportion of type IIB and type IIA fibres and decreased the proportion of type I fibres in the EDL muscles of dystrophic mice. In the soleus muscles of dystrophic mice, IGF-I treatment increased the proportion of type IIA fibres and decreased the proportion of type I fibres. Average fibre cross-sectional area was increased in the EDL and soleus muscles of treated compared with untreated mice. We conclude that IGF-I treatment ameliorates muscle wasting and improves the functional properties of skeletal muscles of dystrophic mice. The findings have important implications for the role of IGF-I in ameliorating muscle wasting associated with the muscular dystrophies. |
| Starting Page | 260 |
| Ending Page | 268 |
| Page Count | 9 |
| File Format | PDF HTM / HTML |
| DOI | 10.1016/S0960-8966(00)00192-9 |
| Alternate Webpage(s) | https://api.elsevier.com/content/article/pii/S0960896600001929 |
| Alternate Webpage(s) | https://www.sciencedirect.com/science/article/pii/S0960896600001929?dgcid=api_sd_search-api-endpoint |
| PubMed reference number | 11297941 |
| Alternate Webpage(s) | https://doi.org/10.1016/S0960-8966%2800%2900192-9 |
| Journal | Medline |
| Volume Number | 11 |
| Journal | Neuromuscular Disorders |
| Language | English |
| Access Restriction | Open |
| Content Type | Text |
| Resource Type | Article |
